- Home
- KZIA vs MTNB Comparison
KZIA vs MTNB Comparison
Compare KZIA & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- MTNB
- Stock Information
- Founded
- KZIA 1994
- MTNB 2013
- Country
- KZIA Australia
- MTNB United States
- Employees
- KZIA N/A
- MTNB N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- MTNB Health Care
- Exchange
- KZIA Nasdaq
- MTNB Nasdaq
- Market Cap
- KZIA 9.0M
- MTNB 9.7M
- IPO Year
- KZIA 1999
- MTNB N/A
- Fundamental
- Price
- KZIA $7.94
- MTNB $1.65
- Analyst Decision
- KZIA Strong Buy
- MTNB Hold
- Analyst Count
- KZIA 2
- MTNB 1
- Target Price
- KZIA $14.00
- MTNB N/A
- AVG Volume (30 Days)
- KZIA 137.3K
- MTNB 87.7K
- Earning Date
- KZIA 11-14-2025
- MTNB 11-12-2025
- Dividend Yield
- KZIA N/A
- MTNB N/A
- EPS Growth
- KZIA N/A
- MTNB N/A
- EPS
- KZIA N/A
- MTNB N/A
- Revenue
- KZIA $1,549,158.00
- MTNB N/A
- Revenue This Year
- KZIA N/A
- MTNB N/A
- Revenue Next Year
- KZIA $49.25
- MTNB N/A
- P/E Ratio
- KZIA N/A
- MTNB N/A
- Revenue Growth
- KZIA 248983.08
- MTNB N/A
- 52 Week Low
- KZIA $2.86
- MTNB $0.47
- 52 Week High
- KZIA $39.05
- MTNB $4.25
- Technical
- Relative Strength Index (RSI)
- KZIA 48.43
- MTNB 49.48
- Support Level
- KZIA $7.60
- MTNB $1.59
- Resistance Level
- KZIA $8.28
- MTNB $1.88
- Average True Range (ATR)
- KZIA 0.51
- MTNB 0.14
- MACD
- KZIA 0.03
- MTNB -0.05
- Stochastic Oscillator
- KZIA 30.88
- MTNB 12.00
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.